Cargando…

Relative contribution of risk factors/co‐morbidities to heart failure pathogenesis: interaction with ejection fraction

AIMS: The relative impact of each individual coexisting morbidity on the pathogenesis of heart failure (HF) is incompletely understood. This study aimed to evaluate the prevalence of individual cardiac and non‐cardiac coexisting morbidities both in the overall HF population and in the subgroup of HF...

Descripción completa

Detalles Bibliográficos
Autores principales: Giamouzis, Grigorios, Xanthopoulos, Andrew, Papamichalis, Michail, Chroub‐Papavaiou, Artemis‐Nantia, Pantziou, Aikaterini, Simou, Anthi, Dimos, Apostolos, Bourazana, Angeliki, Skoularigis, John, Triposkiadis, Filippos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754965/
https://www.ncbi.nlm.nih.gov/pubmed/32949225
http://dx.doi.org/10.1002/ehf2.12975
_version_ 1783626282695655424
author Giamouzis, Grigorios
Xanthopoulos, Andrew
Papamichalis, Michail
Chroub‐Papavaiou, Artemis‐Nantia
Pantziou, Aikaterini
Simou, Anthi
Dimos, Apostolos
Bourazana, Angeliki
Skoularigis, John
Triposkiadis, Filippos
author_facet Giamouzis, Grigorios
Xanthopoulos, Andrew
Papamichalis, Michail
Chroub‐Papavaiou, Artemis‐Nantia
Pantziou, Aikaterini
Simou, Anthi
Dimos, Apostolos
Bourazana, Angeliki
Skoularigis, John
Triposkiadis, Filippos
author_sort Giamouzis, Grigorios
collection PubMed
description AIMS: The relative impact of each individual coexisting morbidity on the pathogenesis of heart failure (HF) is incompletely understood. This study aimed to evaluate the prevalence of individual cardiac and non‐cardiac coexisting morbidities both in the overall HF population and in the subgroup of HF patients with a single coexisting morbidity, stratified by left ventricular ejection fraction (LVEF) categories, as a measure of the relative contribution of each co‐morbidity to the pathogenesis of HF. METHODS AND RESULTS: This is a prospective, observational study, in which unselected ambulatory patients with chronic HF visiting the HF clinic of a tertiary university hospital from January 2016 to January 2019 were classified according to baseline LVEF into three groups: (i) LVEF < 40%, (ii) LVEF = 40–49%, and (iii) LVEF ≥ 50% and then evaluated for various coexisting morbidities. Overall, 1064 patients (age 73.4 ± 12.1 years, male gender 57.7%, LVEF 43.6 ± 13.9, N‐terminal pro‐brain natriuretic peptide 2187 ± 710 ng/L, and estimated glomerular filtration rate 67.2 ± 25 mL/min/1.73 m(2)) were recruited in this study. Of these, 361 (33.9%) had an LVEF < 40%, 247 (23.2%) an LVEF = 40–49%, and 456 (42.9%) an LVEF ≥ 50%. There were 90 (8.5%) HF patients with a single coexisting morbidity, 33 (36.7%) with LVEF ≥ 50%, 27 (30.0%) with LVEF = 40–49%, and 30 (33.3%) with LVEF < 40%. Among these patients, those with LVEF ≥ 50% suffered mostly from hypertension (85.7%), whereas the second most common coexisting morbidity was atrial fibrillation (AF) (9.5%). HF patients with LVEF = 40–49% usually suffered from hypertension (35.7%), AF (28.6%), or myocardial infarction (MI) (21.4%). Finally, HF patients with LVEF < 40% usually suffered from MI (30.8%), AF (30.8%), or hypertension (15.4%). CONCLUSIONS: Hypertension is strongly associated with the development of HF with low, intermediate, or near‐normal/normal LVEF whereas a history of MI or AF with HF with a low or an intermediate LVEF.
format Online
Article
Text
id pubmed-7754965
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-77549652020-12-23 Relative contribution of risk factors/co‐morbidities to heart failure pathogenesis: interaction with ejection fraction Giamouzis, Grigorios Xanthopoulos, Andrew Papamichalis, Michail Chroub‐Papavaiou, Artemis‐Nantia Pantziou, Aikaterini Simou, Anthi Dimos, Apostolos Bourazana, Angeliki Skoularigis, John Triposkiadis, Filippos ESC Heart Fail Short Communications AIMS: The relative impact of each individual coexisting morbidity on the pathogenesis of heart failure (HF) is incompletely understood. This study aimed to evaluate the prevalence of individual cardiac and non‐cardiac coexisting morbidities both in the overall HF population and in the subgroup of HF patients with a single coexisting morbidity, stratified by left ventricular ejection fraction (LVEF) categories, as a measure of the relative contribution of each co‐morbidity to the pathogenesis of HF. METHODS AND RESULTS: This is a prospective, observational study, in which unselected ambulatory patients with chronic HF visiting the HF clinic of a tertiary university hospital from January 2016 to January 2019 were classified according to baseline LVEF into three groups: (i) LVEF < 40%, (ii) LVEF = 40–49%, and (iii) LVEF ≥ 50% and then evaluated for various coexisting morbidities. Overall, 1064 patients (age 73.4 ± 12.1 years, male gender 57.7%, LVEF 43.6 ± 13.9, N‐terminal pro‐brain natriuretic peptide 2187 ± 710 ng/L, and estimated glomerular filtration rate 67.2 ± 25 mL/min/1.73 m(2)) were recruited in this study. Of these, 361 (33.9%) had an LVEF < 40%, 247 (23.2%) an LVEF = 40–49%, and 456 (42.9%) an LVEF ≥ 50%. There were 90 (8.5%) HF patients with a single coexisting morbidity, 33 (36.7%) with LVEF ≥ 50%, 27 (30.0%) with LVEF = 40–49%, and 30 (33.3%) with LVEF < 40%. Among these patients, those with LVEF ≥ 50% suffered mostly from hypertension (85.7%), whereas the second most common coexisting morbidity was atrial fibrillation (AF) (9.5%). HF patients with LVEF = 40–49% usually suffered from hypertension (35.7%), AF (28.6%), or myocardial infarction (MI) (21.4%). Finally, HF patients with LVEF < 40% usually suffered from MI (30.8%), AF (30.8%), or hypertension (15.4%). CONCLUSIONS: Hypertension is strongly associated with the development of HF with low, intermediate, or near‐normal/normal LVEF whereas a history of MI or AF with HF with a low or an intermediate LVEF. John Wiley and Sons Inc. 2020-09-19 /pmc/articles/PMC7754965/ /pubmed/32949225 http://dx.doi.org/10.1002/ehf2.12975 Text en © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Short Communications
Giamouzis, Grigorios
Xanthopoulos, Andrew
Papamichalis, Michail
Chroub‐Papavaiou, Artemis‐Nantia
Pantziou, Aikaterini
Simou, Anthi
Dimos, Apostolos
Bourazana, Angeliki
Skoularigis, John
Triposkiadis, Filippos
Relative contribution of risk factors/co‐morbidities to heart failure pathogenesis: interaction with ejection fraction
title Relative contribution of risk factors/co‐morbidities to heart failure pathogenesis: interaction with ejection fraction
title_full Relative contribution of risk factors/co‐morbidities to heart failure pathogenesis: interaction with ejection fraction
title_fullStr Relative contribution of risk factors/co‐morbidities to heart failure pathogenesis: interaction with ejection fraction
title_full_unstemmed Relative contribution of risk factors/co‐morbidities to heart failure pathogenesis: interaction with ejection fraction
title_short Relative contribution of risk factors/co‐morbidities to heart failure pathogenesis: interaction with ejection fraction
title_sort relative contribution of risk factors/co‐morbidities to heart failure pathogenesis: interaction with ejection fraction
topic Short Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754965/
https://www.ncbi.nlm.nih.gov/pubmed/32949225
http://dx.doi.org/10.1002/ehf2.12975
work_keys_str_mv AT giamouzisgrigorios relativecontributionofriskfactorscomorbiditiestoheartfailurepathogenesisinteractionwithejectionfraction
AT xanthopoulosandrew relativecontributionofriskfactorscomorbiditiestoheartfailurepathogenesisinteractionwithejectionfraction
AT papamichalismichail relativecontributionofriskfactorscomorbiditiestoheartfailurepathogenesisinteractionwithejectionfraction
AT chroubpapavaiouartemisnantia relativecontributionofriskfactorscomorbiditiestoheartfailurepathogenesisinteractionwithejectionfraction
AT pantziouaikaterini relativecontributionofriskfactorscomorbiditiestoheartfailurepathogenesisinteractionwithejectionfraction
AT simouanthi relativecontributionofriskfactorscomorbiditiestoheartfailurepathogenesisinteractionwithejectionfraction
AT dimosapostolos relativecontributionofriskfactorscomorbiditiestoheartfailurepathogenesisinteractionwithejectionfraction
AT bourazanaangeliki relativecontributionofriskfactorscomorbiditiestoheartfailurepathogenesisinteractionwithejectionfraction
AT skoularigisjohn relativecontributionofriskfactorscomorbiditiestoheartfailurepathogenesisinteractionwithejectionfraction
AT triposkiadisfilippos relativecontributionofriskfactorscomorbiditiestoheartfailurepathogenesisinteractionwithejectionfraction